Suppr超能文献

接受个性化肽疫苗治疗的非小细胞肺癌中触珠蛋白基因的单核苷酸多态性

Single nucleotide polymorphisms of the haptoglobin gene in non-small cell lung cancer treated with personalized peptide vaccination.

作者信息

Waki Kayoko, Yamada Teppei, Yoshiyama Koichi, Terazaki Yasuhiro, Sakamoto Shinjiro, Sugawara Shunichi, Takamori Shinzo, Itoh Kyogo, Yamada Akira

机构信息

Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka 830-0011, Japan.

Kurume University Cancer Vaccine Center, Kurume, Fukuoka 830-0011, Japan.

出版信息

Oncol Lett. 2017 Feb;13(2):993-999. doi: 10.3892/ol.2016.5467. Epub 2016 Dec 7.

Abstract

The present study analyzed polymorphisms of the 5' flanking region (from nt -840 to +151) of the haptoglobin gene in 120 patients with advanced non-small cell lung cancer (NSCLC) receiving personalized peptide vaccinations. In the region, six single nucleotide polymorphisms (SNPs) were confirmed, of which two, rs5472 and rs9927981, were completely linked to each other. The minor allele frequencies of rs5472/rs9927981 and rs4788458 were higher than those of the other three SNPs. The genotype frequencies of rs5472 or rs9927981 were A/A or C/C (42.5%, n=51), A/G or C/T (40.8%, n=49), and G/G or T/T (16.7%, n=20), respectively; and those of rs4788458 were T/T (34.2%, n=41), T/C (40.0%, n=48), and C/C (25.8%, n=31). The association between polymorphism rs5472/rs9927981 and prognosis, or between rs4788458 and prognosis, was analyzed further. However, no correlation was found between these SNPs and overall survival, regardless of subgroup analysis of gender, histology or concurrent therapy. These results suggest that the polymorphisms rs5472/rs9927981 and rs4788458 are not useful prognostic tools for patients with NSCLC treated with personalized peptide vaccination.

摘要

本研究分析了120例接受个性化肽疫苗接种的晚期非小细胞肺癌(NSCLC)患者触珠蛋白基因5'侧翼区域(从nt -840至+151)的多态性。在该区域,确认了6个单核苷酸多态性(SNP),其中两个,rs5472和rs9927981,彼此完全连锁。rs5472/rs9927981和rs4788458的次要等位基因频率高于其他三个SNP。rs5472或rs9927981的基因型频率分别为A/A或C/C(42.5%,n = 51)、A/G或C/T(40.8%,n = 49)以及G/G或T/T(16.7%,n = 20);rs4788458的基因型频率分别为T/T(34.2%,n = 41)、T/C(40.0%,n = 48)以及C/C(25.8%,n = 31)。进一步分析了多态性rs5472/rs9927981与预后之间的关联,以及rs4788458与预后之间的关联。然而,无论对性别、组织学或同时进行的治疗进行亚组分析,均未发现这些SNP与总生存期之间存在相关性。这些结果表明,多态性rs5472/rs9927981和rs4788458对于接受个性化肽疫苗接种治疗的NSCLC患者并非有用的预后工具。

相似文献

2
Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients.
Cancer Immunol Immunother. 2015 Dec;64(12):1565-73. doi: 10.1007/s00262-015-1756-7. Epub 2015 Oct 1.
9

本文引用的文献

2
PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer.
Cancer Sci. 2014 Oct;105(10):1229-35. doi: 10.1111/cas.12502. Epub 2014 Sep 23.
3
Genetic factors associated with serum haptoglobin level in a Japanese population.
Clin Chim Acta. 2014 Jun 10;433:54-7. doi: 10.1016/j.cca.2014.02.029. Epub 2014 Mar 12.
4
Personalized peptide vaccine for treatment of advanced cancer.
Curr Med Chem. 2014;21(21):2332-45. doi: 10.2174/0929867321666140205132936.
7
Management of non-small-cell lung cancer: recent developments.
Lancet. 2013 Aug 24;382(9893):709-19. doi: 10.1016/S0140-6736(13)61502-0.
8
ALK inhibitors in the treatment of advanced NSCLC.
Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7.
9
Targeted therapy for non-small-cell lung cancer: past, present and future.
Expert Rev Anticancer Ther. 2013 Jun;13(6):745-58. doi: 10.1586/era.13.47.
10
Next-generation peptide vaccines for advanced cancer.
Cancer Sci. 2013 Jan;104(1):15-21. doi: 10.1111/cas.12050. Epub 2012 Dec 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验